Influenza, Human
216
9
15
176
Key Insights
Highlights
Success Rate
98% trial completion (above average)
Published Results
65 trials with published results (30%)
Research Maturity
176 completed trials (81% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
1.9%
4 terminated out of 216 trials
97.8%
+11.2% vs benchmark
37%
80 trials in Phase 3/4
37%
65 of 176 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 176 completed trials
Clinical Trials (216)
A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age
Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults
A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants
A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above
A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age
Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years
An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection
Intrahospital Influenza Vaccination in Patients at High Cardiovascular Risk (VACC-UP)
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age
A Study About Modified RNA Vaccines Against Influenza in Healthy Adults
Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites
Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)
Flu Infection at UPHS
A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older
Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong
Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures
A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed
Clinical Trials of Quadrivalent Influenza Vaccine